Prepubertal insulin sensitisation in girls with a combined history of low birthweight and precocious pubarche

Submission date	Recruitment status	Prospectively registered		
11/08/2005	No longer recruiting	☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
05/10/2005	Completed	[X] Results		
Last Edited	Condition category	[] Individual participant data		
11/07/2008	Urological and Genital Diseases			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Lourdes Ibanez

Contact details

Hospital Sant Joan de Deu University of Barcelona Esplugues, Barcelona Spain 08950

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Acronym

P&M

Study objectives

Insulin sensitisation delays pubertal onset in low birthweight girls with precocious pubarche.

Please note that as of 11/07/2008, this trial has been updated. All updates can be found in the relevant field under the update date.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 11/07/2008:

Ethics approval received from the Comité de Recerca, Hospital Sant Joan de Déu, University of Barcelona (Spain) on the 11th April 2001. The original protocol was also approved by the Agencia Española del Medicamento (ref: 01-0056, code HSJD-LIT-01). An amendment was presented in January 2008; the absence of reply from the administration implies approval.

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Precocious pubarche

Interventions

Randomised subgroups:

- 1. Metformin 425 mg/day
- 2. Untreated

Added as of 11/07/2008:

Cross-over of therapy from year 6 of follow-up. All patients have been off therapy from year 5 (July 2007) to year 6.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Metformin

Primary outcome measure

Onset of puberty, measured at baseline and every 6 months (timepoints added 11/07/2008)

Secondary outcome measures

- 1. Menarche, measured baseline and every 6 months. All untreated girls are already menarcheal, 14 of 19 treated girls are mernarcheal.
- 2. Final height, measured end of the 6th year

Timepoints added 11/07/2008

Overall study start date

10/10/2002

Completion date

10/10/2007

Eligibility

Key inclusion criteria

Girls with a combined history of low birthweight (less than 1.5 standard deviation score [SDS]) and precocious pubarche (appearance of pubic hair before age 8)

Participant type(s)

Patient

Age group

Child

Sex

Female

Target number of participants

38

Key exclusion criteria

- 1. Congenital adrenal hyperplasia
- 2. Diabetes mellitus
- 3. Thyroid dysfunction

Date of first enrolment 10/10/2002

Date of final enrolment 10/10/2007

Locations

Countries of recruitmentSpain

Study participating centre Hospital Sant Joan de Deu Esplugues, Barcelona Spain 08950

Sponsor information

Organisation

Hospital Sant Joan de Deu (Spain)

Sponsor details

University of Barcelona Passeig de Sant Joan de Deu, 2 Esplugues, Barcelona Spain 08950

Sponsor type

Hospital/treatment centre

Website

http://www.hsjd.org

ROR

https://ror.org/001jx2139

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Hospital Sant Joan de Déu (Spain)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	01/09/2004		Yes	No